ArticleJournal of nanobiotechnology2026
Synergistic microenvironment therapy: a dual-function nanogel of supramolecular collagen ll-mimetic matrix and antioxidant MXene for attenuating intervertebral disc degeneration.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Intervertebral disc degeneration (IVDD) is driven by severe oxidative stress, a loss of extracellular matrix (ECM) homeostasis, and ferroptosis of nucleus pulposus cells (NPCs) as a core pathological mechanism. Therapeutic strategies based on microenvironment engineering that can simultaneously combat oxidative damage and promote tissue repair are urgently needed. Here, we reestablish the IVDD microenvironment using a dual-function nanogel, which integrates a catalytic 2D Mo₂C MXene within a supramolecular Collagen II-mimetic matrix formed by a GFOGER-functionalized self-assembling peptide hydrogel (SAPH). The function of clearing oxidative stress be attribute to the catalytic Mo₂C MXene and the SAPH-R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.